1. Engineering tyrosine residues into hemoglobin enhances heme reduction, decreases oxidative stress and increases vascular retention of a hemoglobin based blood substitute
- Author
-
Leif Bülow, Andras Eke, Gary Silkstone, Thoufieq Shaik, Elizabeth M. Welbourn, Domokos Máthé, Nélida Leiva Eriksson, Svetlana Gretton, Natalie Syrett, Luca Ronda, Badri S. Rajagopal, Andrea Mozzarelli, Brandon J. Reeder, Chris E. Cooper, and Michelle Simons
- Subjects
0301 basic medicine ,Ascorbic Acid ,medicine.disease_cause ,Biochemistry ,Blood substitute ,chemistry.chemical_compound ,Hemoglobins ,Mice ,0302 clinical medicine ,HEK, Human Embryonic Kidney cells ,Tyrosine ,Heme ,Chemistry ,HBOC ,metHb, met(ferric) hemoglobin ,PEGylation ,metMb, met(ferric) myoglobin ,WT, wild type recombinant protein ,Oxidation-Reduction ,medicine.drug ,Iron ,Mice, Nude ,Oxidative phosphorylation ,Hb, Hemoglobin ,Article ,Electron transfer ,Electron Transport ,03 medical and health sciences ,HBOC, Hemoglobin Based Oxygen Carrier ,Blood Substitutes ,Physiology (medical) ,medicine ,Animals ,Humans ,CP20, deferiprone, 1,2-dimethyl-3- hydroxypyrid-4-one ,Hemoglobin ,Methemoglobin ,HbCO, carbon monoxide bound Hb ,oxyHb, oxygenated hemoglobin ,Wild type ,Mb, Myoglobin ,Oxygen ,Oxidative Stress ,030104 developmental biology ,HEK293 Cells ,Oxyhemoglobins ,Ferric ,030217 neurology & neurosurgery ,Oxidative stress - Abstract
Hemoglobin (Hb)-based oxygen carriers (HBOC) are modified extracellular proteins, designed to replace or augment the oxygen-carrying capacity of erythrocytes. However, clinical results have generally been disappointing due to adverse side effects, in part linked to the intrinsic oxidative toxicity of Hb. Previously a redox-active tyrosine residue was engineered into the Hb β subunit (βF41Y) to facilitate electron transfer between endogenous antioxidants such as ascorbate and the oxidative ferryl heme species, converting the highly oxidizing ferryl species into the less reactive ferric (met) form. We inserted different single tyrosine mutations into the α and β subunits of Hb to determine if this effect of βF41Y was unique. Every mutation that was inserted within electron transfer range of the protein surface and the heme increased the rate of ferryl reduction. However, surprisingly, three of the mutations (βT84Y, αL91Y and βF85Y) also increased the rate of ascorbate reduction of ferric(met) Hb to ferrous(oxy) Hb. The rate enhancement was most evident at ascorbate concentrations equivalent to that found in plasma (< 100 μM), suggesting that it might be of benefit in decreasing oxidative stress in vivo. The most promising mutant (βT84Y) was stable with no increase in autoxidation or heme loss. A decrease in membrane damage following Hb addition to HEK cells correlated with the ability of βT84Y to maintain the protein in its oxygenated form. When PEGylated and injected into mice, βT84Y was shown to have an increased vascular half time compared to wild type PEGylated Hb. βT84Y represents a new class of mutations with the ability to enhance reduction of both ferryl and ferric Hb, and thus has potential to decrease adverse side effects as one component of a final HBOC product., Graphical abstract fx1, Highlights • Cell free Hemoglobin Based Oxygen Carriers can deliver oxygen to tissue. • Oxidation of ferrous hemoglobin to ferric and ferryl leads to oxidative toxicity. • Insertion of tyrosine residues enhances reduction of ferryl to ferric hemoglobin. • Some mutants (e.g. βT84Y) also enhance ferric to ferrous reduction by ascorbate. • βT84Y decreases cellular oxidative stress and enhances vascular retention in vivo.
- Published
- 2019